Abbott-Piramal acquisition | Year: May 2010 | Deal size: USD 3.7 billion Objective: To increase its presence in the Indian branded generics space. Result: Expensive deal with Abbott paying 8.8 times of Piramal sales. While the acquisition strengthened Abbott's market position and product portfolio in ...
Read more: From Sun to Cipla - Biggest M&As in the Indian pharma industry that made profits or bombed